Keith Katkin - 30 Apr 2026 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Reporting relationship: Director
Issuer ticker: EBS
Reported as of: 30 Apr 2026
Net transaction value: -$128,183
SEC form: 4
Accepted by SEC: 04 May 2026, 17:29:30 UTC
Prior SEC filing: 06 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Richard S. Lindahl, Attorney-in-fact

Key filing fact

Keith Katkin filed Form 4 for Emergent BioSolutions Inc. (EBS) on 04 May 2026.

Key facts

This page summarizes Keith Katkin's Form 4 filing for Emergent BioSolutions Inc. (EBS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 May 2026, 17:29.

Change

Previous filing in this sequence was filed on 06 Feb 2026.
Current net transaction value: -$128,183.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001314596 Primary reporting owner

Katkin Keith

Relationship: Director
Address: 300 PROFESSIONAL DRIVE, GAITHERSBURG
Signature: /s/ Richard S. Lindahl, Attorney-in-fact
Signature date: 04 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EBS transaction

Common Stock

Award

Transaction value
Shares: +25,344
Change %: +29%
Price: $0.000000^*
Shares after: 111,775
Date: 30 Apr 2026
Ownership: Direct
Footnotes: F1

EBS transaction

Common Stock

Sale

Transaction value: $128,183
Shares: -15,481
Change %: -14%
Price: $8.28
Shares after: 96,294
Date: 30 Apr 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EBS transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares: +11,296
Change %
Price: $0.000000^*
Shares after: 11,296
Date: 30 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,296
Exercise price: $7.99
Footnotes: F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

Footnote F2

Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 10, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.

Footnote F3

The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.23 to $8.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Footnote F4

Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

Footnote F5

The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.